Member Info for scottyboy1966

Hold my hands up, I am one of the herd. I have seen a couple of people posting in SYME, about this share and jumped in on the spike without doing any research... that`ll teach me hey. Will do my research now and hopefully stay here for the duration and get my money back.

Lesson learnt... DYOR

and to rub salt in the wound... Avacta`s shares go up on no news. MM`s really messing with this share price

Still waiting ;-)

Just top up boys and girls. Don`t panic sell because in time this is going to rocket. So don`t give your shares to the MM`s

GLA

3277728 shares and here for the long haul.... will keep topping up along the way as this is going to me huge !!!

Thanks Weathergeek. You are another informative poster whose information I value

Hey Oz.... You seem to be clued up on this relatively new company... In your opinion, where do you see the SP going to in the next five years. Hard to forecast I know but the future is certainly very bright I think

PS Thanks for all the great info you post. It certainly adds a little security when investing in new companies.

So the question has to be asked, is our test really good enough. The UK government know all about it and would love to be the ones who save the planet. So why aren't they rolling it out, is it not good enough, is it too expensive, what is the answer to the £64 million dollar question?

AVCT about to explode

BOOM ;-)

Cheers Micky....really appreciate your insight. Good luck

Hey Micky.... how soon is soon... these shares have stalled a little. I need to stop looking at them every 2 minutes ;-)

3.3 million at 0.311

I am already in SKIN but have to admit I have sold all my AVCT. Split it 50/50 last Friday with 7DIG and SYME after tip offs on here and getting despondant with the wait. Turned out to be a great move but shall be back here soon.

GLA

Thanks Micky1. I am not letting go of this for the world. Stumbled across it and invested £10k . Do you have any indication of timescales for the above.

Good luck to all

I am expecting a bit of a jump this afternoon. I know the Americans can trade now but a lot will be asleep. Once they wake up and start pumping into this, we may see another rise.

Good luck to all

Tonight is like being a child on Christmas eve. The anticipation of what the morning will bring is overwhelming. I have only been trading since lockdown and this company is going to be a life changer.

Good luck to all invested

3.5 million but hoping to get a lot more. Just need Avacta to come good so I can top slice. All about timing

GLA

I wouldn't of top sliced out of SYME just yet. It is going to be huge and ODX is a slos burner. IMO of course. Good luck

Skip to Content
Toggle NavBBI SolutionsMy Cart
Search
For those who have not seen it yet :

BBI Solutions Partners with Avacta Group PLC as COVID-19 Rapid Antigen Test Manufacturer
08/06/2020
BBI Solutions Partners with Avacta Group PLC as COVID-19 Rapid Antigen Test Manufacturer

BBI Solutions is pleased to announce it has been appointed to manufacture the saliva-based rapid SARS-COV-2 antigen test that is being developed by Affimer® biotherapeutics and reagents developer Avacta Group plc (AIM: AVCT) in conjunction with Cytiva.

South Wales based BBI Solutions is a leading global developer and manufacturer of raw materials and finished test products for the in-vitro diagnostics market with manufacturing sites in five different countries, spanning four continents.

Dr. Mario Gualano, Chief Executive of BBI Group, said: “BBI are delighted to have been appointed to lead the manufacture of Avacta’s rapid coronavirus antigen test and to be able to further extend our lateral flow expertise to addressing the global challenges presented by COVID-19.

“Our ability to respond rapidly to Avacta’s needs is testament to our team’s diagnostic expertise and the supporting manufacturing and quality systems we have implemented at our ISO13485 accredited facility.”

The manufacturing agreement between BBI and Avacta announced today comprises accelerated development and validation of a scaled-up manufacturing process that has the potential to ramp up to a production capacity of millions of tests per month. Avacta, Cytiva and BBI are in the process of technology transfer of the prototype and related manufacturing procedures for the saliva-based rapid COVID-19 antigen test from Cytiva to BBI.

Avacta aims to begin clinical validation of the test as soon as possible by using the first pilot batches generated as part of the technology transfer process for these studies. In parallel with these clinical validation studies, which will be run within the UK government’s CONDOR programme and potentially with other collaborators globally, BBI will work with Avacta and Cytiva to produce the additional technical documentation that is required for CE marking of the final product.

Dr. Alastair Smith, Chief Executive of Avacta Group commented: “I am delighted to be working with BBI to manufacture the rapid coronavirus antigen test. BBI has been excellent to work with to define a highly compressed product development timeline that will allow us to get product to market as quickly as possible.

“We anticipate very high demand for the COVID-19 rapid test and will be working with our preferred manufacturing partners at BBI to satisfy that demand. We are actively continuing our discussions with other manufacturing partners to ensure that we have access to additional manufacturing capacity to address the global need for SARS-COV-2 antigen testing in the next few years.

“As we set out in the use of proceeds at the rec